MIT spinout Boltz launched as a public-benefit company with a $28 million seed round to deliver open AI platforms for drug discovery, claiming AlphaFold‑level complex prediction and agents for small-molecule design. The company said its tools aim to let scientists progress from hypothesis to candidate without leaving the desktop. Source: GEN. Separately, FRAIL technology—fragment-based reinforcement learning—was reported to accelerate molecular optimization by combining reinforcement learning with fragment strategies. Both moves illustrate how computational platforms are moving from labs to commercial products and investor-backed companies. Investors and drug developers will watch real-world validations, IP strategy and integration with existing discovery workflows to assess whether these AI-first platforms materially shorten timelines and reduce costs.